Mural Oncology PLC (MURA)
(Delayed Data from NSDQ)
$1.78 USD
0.00 (0.00%)
Updated Aug 6, 2025 04:00 PM ET
After-Market: $1.82 +0.04 (2.25%) 5:48 PM ET
3-Hold of 5 3
F Value D Growth A Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
MURA 1.78 0.00(0.00%)
Will MURA be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for MURA based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for MURA
MURA Soars as it Explores Strategic Options Post Cancer Study Failures
MURA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for MURA
MURA Restructures Operations Amid Financial Conservation Efforts
Mural Oncology Announces Second Quarter Financial Results and Provides Business Update | MURA ...
Mural Oncology reports Q2 EPS ($2.78) vs ($1.86) last year
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Prosight Management, LP's Strategic Acquisition in Mural Oncology PLC